Navigation Links
Can tomatoes carry the cure for Alzheimer's?
Date:7/8/2008

The humble tomato could be a suitable carrier for an oral vaccine against Alzheimer's disease, according to HyunSoon Kim from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) in Korea and colleagues from Digital Biotech Inc. and the Department of Biological Science at Wonkwang University. Although their research (1), just published online in Springer's journal Biotechnology Letters, is still in the early stages, it is a promising first step towards finding an edible vaccine against the neurodegenerative disease.

Alzheimer's disease is the most common cause of dementia and it progresses over a long period of time. It is thought to be caused by the accumulation of human beta-amyloid, a toxic insoluble fibrous protein in the brain, which leads to the death of neurons. Reducing the accumulation of beta-amyloid may inhibit the degeneration of the nervous system and therefore prevent or delay the onset of Alzheimer's disease. One approach is to stimulate the immune system to reduce beta-amyloid in the brain.

Kim and colleagues' aim was to develop a plant-derived vaccine against Alzheimer's disease, since beta-amyloid is toxic to animal cells. Tomatoes are an attractive candidate as a vaccine carrier because they can be eaten without heat treatment, which reduces the risk of destroying the immune stimulation potential of the foreign protein. The researchers inserted the beta-amyloid gene into the tomato genome and measured the immune responses to the tomato-derived toxic protein in a group of 15-month-old mice.

They immunized the mice orally with the transgenic tomato plants once a week for three weeks, and also gave the mice a booster seven weeks after the first tomato feed. Blood analyses showed a strong immune response after the booster, with the production of antibodies to the human foreign protein.

The authors conclude: "Although we did not reveal a reduction of existing plaques in the brain of mice challenged with tomato-derived beta-amyloidthis study represents a unique approach in which transgenic plants expressing beta-amyloid protein are used to produce a vaccine." The team is currently looking at strategies to increase the potency of the tomato-based vaccine, because fresh tomatoes contain only 0.7% protein and levels of foreign protein are even lower.


'/>"/>

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer
Source:Eurekalert

Related biology news :

1. Certain form of tomatoes could be key to prostate cancer prevention
2. Poultry workers at increased risk of carrying antibiotic-resistant E. coli
3. 100 percent of people carry at least 1 type of pesticide
4. Environmental fate of nanoparticles depends on properties of water carrying them
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/9/2016)... Finland , June 9, 2016 ... National Police deploy Teleste,s video security solution to ensure the ... France during the major tournament ... data communications systems and services, announced today that its video ... Prefecture to back up public safety across the ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 02, 2016 , ... In ... cervical and lumbar disc production, company President, Jake Lubinski will be traveling to ... the AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of ...
(Date:12/2/2016)... 2, 2016 Amgen (NASDAQ: AMGN ) ... the submission of a Marketing Authorization Application (MAA) to the ... to Avastin ® (bevacizumab). The companies believe this submission ... "The submission of ABP 215 to the ... our oncology portfolio," said Sean E. Harper , M.D., ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced ... I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking ... update on the phase I/II clinical trials for AC0010 in patients with advanced non-small ...
(Date:12/2/2016)... ... December 01, 2016 , ... PhUSE will build on the ... US Single Day Events (SDE) to organize a multiple-day US conference. The first ... Topics of the pharmaceutical and life sciences industry will cover industry standards, data ...
Breaking Biology Technology: